ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT

  • November 17, 2026

Share

  • 1

    Antonio Giordano, MD, PhD, presented data from the phase 2 FOURLIGHT-1 study.

  • 2

    FOURLIGHT-1 evaluated atirmociclib plus fulvestrant in advanced HR-positive, HER2-negative breast cancer.

  • 3

    The study involved patients whose disease had progressed after prior CDK4/6 inhibitor treatment.

  • 4

    The presentation addressed the efficacy of atirmociclib plus fulvestrant.

  • 5

    The presentation also addressed the safety of atirmociclib plus fulvestrant.

Original Source(s)

Related Content